Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 dose-ranging prophylaxis in hereditary angioedema
2015-003923-74Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of berotralstat in hereditary angioedema (HAE) (4 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Weekly confirmed HAE attack rate. Started Nov 2015; status: terminated.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2015-003923-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003923-74.